gastrointestinal diseases

Ursodeoxycholic acid sodium (Sodium Ursodeoxycholate) is a naturally occurring secondary bile acid with anti-inflammatory and cytoprotective activities. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors,

Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5). Ursodeoxycholic acid inhibits cholesterol absorption and is used to dissolve gallstones.

Benzamide Derivative 1 Benzamide derivative with gastrokinetic activity.Benzamide Derivative 1 can be used in the study of gastrointestinal diseases.

Indazole is also called benzpyrazole or isoindazone. Its derivatives exhibit a wide range of biological activities. Indazole and its derivatives can be used in the research of cancer, neurological diseases, cardiovascular diseases, and gastrointestinal diseases.

5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 of 33.4 nM, suitable for studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease, or gastrointestinal disease [1] [2].

Substance P Receptor Antagonist 1 has potential applications in treating gastrointestinal disorders, inflammatory diseases, respiratory conditions, and central nervous system disorders.

Omeprazole-d3 is a stable deuterated derivative of omeprazole. Omeprazole is a selective proton pump inhibitor (PPI) used in research related to gastrointestinal diseases. Omeprazole inhibits the proliferation and adhesion of Helicobacter pylori and disrupts the stability of the bacterial cell membrane. Omeprazole inhibits the growth of both Gram-positive and Gram-negative bacteria.

Ontunisertib (Example 26) is a TGFβ receptor I/ALK5 (TGFβRI/ALK5) inhibitor with an IC50 value range of 100-500 nM for TGFβRI and an IC50 value of ≤100 nM for ALK5. This compound is applicable for research in gastrointestinal diseases, fibrosis-related conditions of the skin and eyes, and cancer.

Dexbrompheniramine is an antihistamine with anticholinergic properties. It is used to treat allergic diseases such as hay fever or urticaria. It can compete with histamine for H1 receptor sites on effector cells of the gastrointestinal tract, blood vessel

Nocloprost (SH 475) is a prostaglandin E2 (PGE2) analog, an EP1 and EP3 receptor agonist with local gastric protection and ulcer healing activity, reducing aspirin-induced gastrointestinal lesions, and inducing platelet activation, useful for studying cardiovascular diseases.

β-Defensin-3 (human) trifluoroacetate salt (hBD-3) is a key antimicrobial peptide in the human innate immune system, exhibiting broad-spectrum bactericidal, immunomodulatory, and tissue-repairing activities. β-Defensin-3 (human) trifluoroacetate salt can be used in the treatment of skin diseases and cancer, as well as in research on drug-resistant bacterial infections.

Fulvic Acid is a natural product of humus produced by microorganisms in soil, sediment or aquatic environments. Fulvic acid is a phenolic acid and fungal metabolite isolated from Penicillium for the first time. Fulvic Acid inhibits the dimerization of amyloid b (17-42) (AB17-42), destroys the pre-formed trimer of AB17-42, and binds to the catalytic site of phosphodiesterase 5A (PDE5A), which can regulate the body's immune system, affect the oxidation state of cells, and improve gastrointestinal function. Fulvic Acid can be used as an oxidant or reducing agent and has the potential to study chronic inflammatory diseases such as diabetes.

Linaprazan glurate inhibits both exogenously and endogenously stimulated gastric acid secretion and can be utilized in studies on gastrointestinal inflammatory diseases and peptic ulcer diseases.

Zastaprazan (JP-1366, compound 6) is a potassium-competitive acid blocker and proton pump inhibitor that suppresses gastric acid secretion, indicated for gastro-oesophageal reflux disease (GERD).

Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and has the potential for treating other gastrointestinal diseases.

Isopropamide iodide is a long-acting anticholinergic drug used for peptic ulcers and other gastrointestinal disorders, and as a muscarinic receptor antagonist for diseases affecting cognition [including Alzheimer's disease].

Neratinib maleate (HKI-272 maleate) is an irreversible, orally active and highly selective inhibitor of HER2 and EGFR with IC50 values of 59 nM and 92 nM, respectively.Neratinib maleate has antitumor activity and can be used to treat gastrointestinal, respiratory, genitourinary, and cutaneous and musculoskeletal diseases, and can be used to study breast and prostate cancer. used in the study of breast and prostate cancer.

Ritivixibat is an ileal bile acid transporter (IBAT) inhibitor and bile acid modulator. It is utilized in research related to cardiovascular diseases, fatty acid metabolism disorders, glucose utilization abnormalities, gastrointestinal conditions, and liver diseases.

LON63114, also known as FFA2-Agonist-1 is a selective orthosteric agonist of human FFA2. FFA2-Agonist-1 is potentially useful in the treatment of gastrointestinal disorders and inflammatory bowel diseases. LON63114 was reported in WO2011076732. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

(R)-Tegoprazan, a benzimidazole derivative, serves as a potent inhibitor of kidney H+/K+-ATPase, demonstrating significant efficacy with an IC50 of 98 nM against canine kidney Na+/K+-ATPase. This compound shows promise for research in gastrointestinal diseases.

PDE5-IN-4, a phosphodiesterase 5 (PDE5) inhibitor, is utilized in research concerning acute myocardial infarction and reperfusion-related damage, gastrointestinal diseases, diabetic complications, and liver failure.

Irpagratinib (ABSK011) is an orally active and highly effective FGFR4 antagonist with antitumor activity, inhibiting FGFR4 autophosphorylation and blocking FGFR4 signaling to downstream pathways. It is used in studies of gastrointestinal diseases and cancer.

Catechin 7-O-β-D-glucopyranoside is a major bioactive constituent associated with antioxidant and anti-inflammatory benefits of PHCR seed extracts and has been recognized as a promising research agent for intestinal inflammatory disorders. Catechin 7-O-β-D-glucopyranoside demonstrates strong biological effects supporting future pharmaceutical development of CGP-containing formulations against gastrointestinal inflammatory diseases.

MAO-IN-5 (Compound ZINC000016952895), a monoamine oxidase (MAO) inhibitor, demonstrates properties such as inhibiting the CYP enzyme family, permeability across the blood-brain barrier (BBB), and high gastrointestinal absorption. These characteristics make MAO-IN-5 a potentially valuable agent in researching neurological diseases [1].